Evidence map›Paper›PMID 31534232›Full record

ArticleNature protocols2019

Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging.

Ziming Du, Jia-Ren Lin, Rumana Rashid, Zoltan Maliga, Shu Wang, Jon C Aster, Benjamin Izar, Peter K Sorger, Sandro Santagata

Open access · greenAbstract read
In one paragraph

Article in Nature protocols, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed, 1 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 1 synthesis or guideline pooled it, 139 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. T cell receptors for antigen on intraepithelial cytolytic T lymphocytes in celiac disease engage enterocyte HLA-E and HLA-B.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Ziming Du *Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Jia-Ren Lin *Ludwig Center for Cancer Research at Harvard, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-4702-7705
Rumana Rashid *Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Zoltan MaligaLudwig Center for Cancer Research at Harvard, Harvard Medical School, Boston, MA, USA.
Shu WangLudwig Center for Cancer Research at Harvard, Harvard Medical School, Boston, MA, USA.
Jon C AsterDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Benjamin IzarLudwig Center for Cancer Research at Harvard, Harvard Medical School, Boston, MA, USA.
Peter K SorgerLudwig Center for Cancer Research at Harvard, Harvard Medical School, Boston, MA, USA. peter_sorger@hms.harvard.edu.ORCID http://orcid.org/0000-0002-3364-1838
Sandro SantagataDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. ssantagata@bics.bwh.harvard.edu.ORCID http://orcid.org/0000-0002-7528-9668
Brigham and Women's Hospital · USHarvard University · USBroad Institute · US

Funding

VectorP30CA006516 · NCI · DANA-FARBER CANCER INSTITUTE · PI A. Heather Eliassen · 1985 to 2026
$330.6M
MOLECULAR BIOPHYSICS TRAINING GRANTT32GM008313 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI MURTHY, VENKATESH N · 1989 to 2023
$14.6M
Systems Pharmacology of Therapeutic and Adverse Responses to ImmuneCheckpoint and Small Molecule DrugsU54CA225088 · NCI · HARVARD MEDICAL SCHOOL · PI SORGER, PETER KARL · 2018 to 2022
$10.8M
Omic and Multidimensional Spatial Atlas of Metastatic Breast CancerU2CCA233280 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI GOECKS, JEREMY · 2018 to 2023
$9.7M
Pre-cancer atlases of cutaneous and hematologic origin (PATCH Center)U2CCA233262 · NCI · HARVARD MEDICAL SCHOOL · PI SANTAGATA, SANDRO, SORGER, PETER KARL · 2018 to 2023
$8.7M
Dissecting mechanisms of immunotherapy resistance in melanoma patientsK08CA222663 · NCI · DANA-FARBER CANCER INST · PI IZAR, BENJAMIN · 2017 to 2021
$827k
Highly Multiplexed Analysis of Solid Tumors and Liquid Tissues by Cyclic ImmunofluorescenceR41CA224503 · NCI · RARECYTE, INC. · PI KALDJIAN, ERIC · 2018 to 2018
$224k
NCI NIH HHS K08 CA222663NCI NIH HHS P30 CA006516NCI NIH HHS R41 CA224503NCI NIH HHS U2C CA233262NCI NIH HHS U2C CA233280NCI NIH HHS U54 CA225088NIGMS NIH HHS T32 GM008313
6 · The paper itself

Abstract

Multiplexed tissue imaging enables precise, spatially resolved enumeration and characterization of cell types and states in human resection specimens. A growing number of methods applicable to formalin-fixed, paraffin-embedded (FFPE) tissue sections have been described, the majority of which rely on antibodies for antigen detection and mapping. This protocol provides step-by-step procedures for confirming the selectivity and specificity of antibodies used in fluorescence-based tissue imaging and for the construction and validation of antibody panels. Although the protocol is implemented using tissue-based cyclic immunofluorescence (t-CyCIF) as an imaging platform, these antibody-testing methods are broadly applicable. We demonstrate assembly of a 16-antibody panel for enumerating and localizing T cells and B cells, macrophages, and cells expressing immune checkpoint regulators. The protocol is accessible to individuals with experience in microscopy and immunofluorescence; some experience in computation is required for data analysis. A typical 30-antibody dataset for 20 FFPE slides can be generated within 2 weeks.

Indexed as

AntibodiesAnimalsBiomarkers, TumorFluorescent Antibody TechniqueFormaldehydeHumansImage Processing, Computer-AssistedImmunohistochemistryMiceNeoplasmsParaffin EmbeddingAntibodiesBiomarkers, TumorFormaldehyde

Identifiers

PMID31534232
PMCPMC6959005
OpenAlexW2973401242

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.